The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2025 |
Yuxuan Lin, Yonghe Liao, Bo Luo, Jinhai Shen. First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials, Frontiers in Immunology. 2025; 16: 1667793. https://doi.org/10.3389/fimmu.2025.1667793 |
|
2 |
2025 |
Jing Xu, Xin Wang, Zhenya Jia, Guoping Sun. Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study, Medicine. 2025; 104: e41814. https://doi.org/10.1097/MD.0000000000041814 |
|
3 |
2025 |
V. A. Valishin, K. V. Menshikov, A. V. Sultanbaev, R. R. Abdeev, R. R. Urazin, Sh. I. Musin, L. A. Valishina, V. I. Zgonikov, R. T. Ayupov, I. N. Startsev-Svetlichny. Conversion therapy for hepatocellular carcinoma: a case report, Siberian journal of oncology. 2025; 24: 170. https://doi.org/10.21294/1814-4861-2025-24-4-170-177 |
|
4 |
2025 |
Qing Bao, Haoming Chen, Song Wu, Zhi Tian, Hailin Tang. Role of immune checkpoint inhibitors in breast cancer and hematological malignancies, Exploration of Immunology. 2025; 5: 1003220. https://doi.org/10.37349/ei.2025.1003220 |